GleamWall
中文EN

AVTX Avalo Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534120 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-77.1%
TTM net income YoY-11.4%
TTM EPS YoY81.6%
Revenue 3-yr CAGR-56.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15,536.1%
Net margin-7,965.8%
FCF margin-11,123.8%
EBITDA margin-15,497.7%

Returns

ROE-50.1%
ROA-40.9%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets11.7%
Debt / equity0.00x
Current ratio19.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio16.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$59,000$441,000
R&D expense$50.08M$24.44M
SG&A expense$22.90M$17.24M
Operating income-$72.92M-$68.51M
Pretax income-$78.09M-$35.02M
Income tax$165,000$114,000
Net income-$78.26M-$35.13M
EBITDA-$72.58M-$68.34M
EPS (basic)-5.84-7.94
EPS (diluted)-5.84-20.91
Weighted avg. shares (diluted)13.40M7.50M
Balance sheet
Cash & equivalents$15.86M$134.70M
Short-term investments$82.48M$0
Current assets$105.29M$138.89M
Goodwill$10.50M$10.50M
Total assets$116.46M$150.73M
Current liabilities$12.94M$6.96M
Total liabilities$33.41M$17.70M
Shareholders' equity$83.05M$133.03M
Shares outstanding18.51M10.47M
Cash flow statement
Operating cash flow-$51.46M-$49.06M
Capital expenditure—$0
Free cash flow—-$49.06M
Investing cash flow-$81.72M$356,000
Financing cash flow$14.59M$175.85M
Depreciation & amortization$344,000$169,000
Stock-based compensation$13.62M$5.85M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.